WO2002076173A3 - Inhibitors of glycosaminoglycans - Google Patents
Inhibitors of glycosaminoglycans Download PDFInfo
- Publication number
- WO2002076173A3 WO2002076173A3 PCT/US2002/011167 US0211167W WO02076173A3 WO 2002076173 A3 WO2002076173 A3 WO 2002076173A3 US 0211167 W US0211167 W US 0211167W WO 02076173 A3 WO02076173 A3 WO 02076173A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycosaminoglycan
- peptide derivatives
- peptides
- sulfate
- chitosan
- Prior art date
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001661 Chitosan Polymers 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229920002101 Chitin Polymers 0.000 abstract 1
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract 1
- 229920000045 Dermatan sulfate Polymers 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229920000288 Keratan sulfate Polymers 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 abstract 1
- 229940059329 chondroitin sulfate Drugs 0.000 abstract 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
- 229940051593 dermatan sulfate Drugs 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 230000007781 signaling event Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of glycosaminoglycan-mediated signaling events and targeting agents. Peptides of the invention may be directed against any glycosaminoglycan, including hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2. The peptide derivatives of the invention also have therapeutic uses in the treatment and prevention of diseases involving inflammatory diseases, cancer, and cancer metastasis, autoimmune diseases, etc.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002258749A AU2002258749A1 (en) | 2001-03-21 | 2002-03-20 | Inhibitors of glycosaminoglycans |
| JP2002574703A JP2004532203A (en) | 2001-03-21 | 2002-03-20 | Glycosaminoglycan inhibitors |
| EP02728711A EP1430302A4 (en) | 2001-03-21 | 2002-03-20 | Inhibitors of glycosaminoglycans |
| CA002439409A CA2439409A1 (en) | 2001-03-21 | 2002-03-20 | Inhibitors of glycosaminoglycans |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27779001P | 2001-03-21 | 2001-03-21 | |
| US60/277,790 | 2001-03-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002076173A2 WO2002076173A2 (en) | 2002-10-03 |
| WO2002076173A3 true WO2002076173A3 (en) | 2004-04-08 |
Family
ID=23062353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/011167 WO2002076173A2 (en) | 2001-03-21 | 2002-03-20 | Inhibitors of glycosaminoglycans |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1430302A4 (en) |
| JP (1) | JP2004532203A (en) |
| AU (1) | AU2002258749A1 (en) |
| CA (1) | CA2439409A1 (en) |
| WO (1) | WO2002076173A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2279291B1 (en) * | 2008-04-09 | 2019-07-03 | Cornell University | Coferons and methods of making and using them |
| EP2485678A4 (en) | 2009-10-07 | 2013-04-03 | Univ Cornell | Coferons and methods of making and using them |
| EP2804586A4 (en) * | 2012-01-19 | 2016-03-16 | Univ Johns Hopkins | Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995011924A1 (en) * | 1993-10-27 | 1995-05-04 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| WO1997009051A1 (en) * | 1995-09-05 | 1997-03-13 | Cambridge Neuroscience, Inc. | Analogs for specific oligosaccharide-neuregulin interactions and uses thereof |
| WO2000001841A2 (en) * | 1998-07-06 | 2000-01-13 | Prestwich Glenn D | Hyaluronic acid mimics and methods related thereto |
| WO2000068263A2 (en) * | 1999-05-05 | 2000-11-16 | Neurochem, Inc. | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040189A1 (en) * | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| CA2237051A1 (en) * | 1997-12-19 | 1999-06-19 | Eva A. Turley | Enhanced affinity hyaluronan binding peptides |
| DK1165112T3 (en) * | 1999-03-26 | 2006-10-09 | Univ Texas | Modulators of polysaccharides and their applications |
-
2002
- 2002-03-20 WO PCT/US2002/011167 patent/WO2002076173A2/en active Search and Examination
- 2002-03-20 AU AU2002258749A patent/AU2002258749A1/en not_active Abandoned
- 2002-03-20 EP EP02728711A patent/EP1430302A4/en not_active Withdrawn
- 2002-03-20 JP JP2002574703A patent/JP2004532203A/en active Pending
- 2002-03-20 CA CA002439409A patent/CA2439409A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995011924A1 (en) * | 1993-10-27 | 1995-05-04 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| WO1997009051A1 (en) * | 1995-09-05 | 1997-03-13 | Cambridge Neuroscience, Inc. | Analogs for specific oligosaccharide-neuregulin interactions and uses thereof |
| WO2000001841A2 (en) * | 1998-07-06 | 2000-01-13 | Prestwich Glenn D | Hyaluronic acid mimics and methods related thereto |
| WO2000068263A2 (en) * | 1999-05-05 | 2000-11-16 | Neurochem, Inc. | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1430302A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002258749A1 (en) | 2002-10-08 |
| EP1430302A2 (en) | 2004-06-23 |
| WO2002076173A2 (en) | 2002-10-03 |
| EP1430302A4 (en) | 2007-08-22 |
| CA2439409A1 (en) | 2002-10-03 |
| JP2004532203A (en) | 2004-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105531T1 (en) | POLYSACCHARIDE REGULATORS AND THEIR USES | |
| IL267381A (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| WO2002023190A8 (en) | Methods and products related to low molecular weight heparin | |
| WO2010005310A3 (en) | Complement antagonists and uses thereof | |
| CA2286552A1 (en) | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine | |
| WO2006131392A8 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| IL223875A (en) | Use of chondroitinase in the preparation of a medicament for use in a method of promoting neuronal plasticity | |
| NZ333925A (en) | Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus | |
| WO2008037380A3 (en) | Alkyl benzoate mixtures | |
| WO2004105737A3 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
| NZ530037A (en) | Use of glycosaminoglycans for the treatment of HIV-associated nephropathy | |
| AU5218001A (en) | Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals | |
| ATE381957T1 (en) | USE OF AN ANTIFUNGAL ECHINOCANDIN AGENT IN COMBINATION WITH AN ANTIBACTERIAL GLYCOPEPTIDE AGENT | |
| FR2866571B1 (en) | USE OF A MIXTURE OF SPECIFIC POLYSACCHARIDES AS INDICATED BY THE EZBONE INVENTOR COMPRISING HYALURONIC ACID, CHONDROID SULFATE, DERMATANE SULFATE AND HEPARIN IN BONE HEALING. | |
| HK1074582A1 (en) | Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd | |
| AU4651700A (en) | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases | |
| WO2002076173A3 (en) | Inhibitors of glycosaminoglycans | |
| CA2472093A1 (en) | Use of sulfated glycosaminoglycans for establishing effective labor in women | |
| WO2004108069A3 (en) | Compositions and methods for promoting neuronal outgrowth | |
| HK1066163A1 (en) | Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate | |
| JP2002145779A5 (en) | ||
| GB0616311D0 (en) | Glycosaminoglycan peptides derived from connective tissues and use thereof in the prevention of arthritis and other degenerative medical conditions | |
| WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
| WO2005013946A3 (en) | Methods of treatment inflammatory bowel with lxr agonists | |
| WO2002067954A3 (en) | Use of particulate biocomplex bk-riv for producing a medicament for protecting and reconstructing the hepatic parenchyma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2439409 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002574703 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002728711 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWP | Wipo information: published in national office |
Ref document number: 2002728711 Country of ref document: EP |